415
Views
0
CrossRef citations to date
0
Altmetric
News & Views

INTERVIEW: Key Questions in Pain Research: Clinical Observations Informing Research and vice versa

Pages 123-125 | Published online: 02 Mar 2011
 

Abstract

Dr David Bennett received his MB PhD qualification from the United Medical and Dental Schools of Guy‘s and St Thomas‘ London (UK) in 1999. He undertook an intercalated PhD studying the role of neurotrophic factors in sensory neuronal development and plasticity in the department of physiology under the supervision of Steven McMahon and John Priestley. Subsequent work investigated the importance of neurotrophic factors in the response to nerve injury. Subspecialty training in neurology took place principally in London at the National Hospital for Neurology and Neurosurgery, King‘s College Hospital, and Guy‘s and St Thomas‘ NHS Trust. Since 2009, Dr Bennett has been a consultant neurologist at King‘s College Hospital and provides a specialist clinical service for the investigation and treatment of peripheral neuropathy and neuropathic pain. He is currently a Wellcome clinical scientist and his research focuses on understanding the neurobiology of nerve injury and the development of neuropathic pain. He is a member of the Wellcome Trust-funded London Pain Consortium and Vice-Director of the ‘Europain‘ Investigational Medicines Initiative. He is also an Associate Editor of Pain Management.

Financial & competing interests disclosure

D Bennett receives research funding from the Europain Investigational Medicines Initiative, which is a Public–Private Partnership between the pharmaceutical industry and the EU. D Bennett has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

D Bennett receives research funding from the Europain Investigational Medicines Initiative, which is a Public–Private Partnership between the pharmaceutical industry and the EU. D Bennett has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.